BDNF levels are not related with levodopa-induced dyskinesias in MPTP monkeys
✍ Scribed by Pershia Samadi; Marc Morissette; Daniel Lévesque; Thérèse Di Paolo
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 438 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Levodopa‐induced dyskinesias (LIDs) are frequent in parkinsonian patients and may result from an aberrant plasticity. Brain‐derived neurotrophic factor (BDNF) represents a likely candidate to subserve neuroadaptive processes encountered in LIDs. We compared striatal BDNF levels measured by ELISA in levodopa‐treated 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) monkeys having developed LIDs compared with animals where LIDs were prevented by the addition of CI‐1041 (NR1A/2B NMDA receptor antagonist) or low doses of cabergoline (dopamine D2 receptor agonist). We observed reduced striatal BDNF concentrations in levodopa‐treated MPTP monkeys with or without LIDs, suggesting that levodopa treatment is associated with reduced striatal BDNF levels and is independent of dyskinesias. © 2009 Movement Disorder Society